Delstrigo (Doravirine/Lamivu/Tenofov Diso) Patent Expiration, LOE Window & CMS Spending

Delstrigo (Doravirine/Lamivu/Tenofov Diso) by Merck & Co.: FDA Orange Book core substance LOE 2032-08-30 (last listed 2036-11-29), 0 AB generics, $34.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN210807 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-08-30
Last Listed Patent or Exclusivity Date2036-11-29
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$34.8M
2024 Medicare Part D Spend$18.5M
2024 Medicaid Spend$16.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.